Russell (Bo) Kowalczyk - Vice President, Global Sales and Marketing
Saint Charles, MO – January 12, 2018
Eurofins Pharma Bioanalytical Services, a leading provider of large molecule bioanalytical testing services is pleased to announce the appointment of Russell (Bo) Kowalczyk to the role of Global Vice President, Sales and Marketing. Mr. Kowalczyk will lead the global business development and marketing teams to develop new service solutions and create new opportunities to grow in line with client demands.
This appointment is the latest in a series of strategic hires designed to best respond to and anticipate the growing needs of clients who require expertise and experience in conducting large molecule preclinical and clinical studies.
"Mr. Kowalczyk brings a unique set of professional experiences in the large molecule bioanalytical market that will enhance understanding of our clients’ needs so we can continue to build strong relationships with our clients focusing on performance, transparency and ultimately customer satisfaction”, said Christina Shasserre, Senior Vice President Eurofins Pharma Discovery and Bioanalytical Services.
Mr. Kowalczyk studied and earned degrees in Chemistry (BS) and Organic Synthesis (MS) prior to becoming focused on the commercial side of the life sciences and contract research industries, where he has worked for 25 years. Most recently, he served as VP of Business Development where he oversaw strategic planning, sales development and marketing. His experience also includes sales and marketing roles at ABC Laboratories (now EAG-Eurofins), Isotec (division of Sigma-Aldrich), SGS Life Sciences, and AIT Bioscience.
He earned his MBA in Marketing & Management from University of Illinois.
For more information, please contact us
About Eurofins Pharma Bioanalytical Services- a global leader in large molecule bioanalysis
Eurofins Bioanalytical Services is a powerhouse large molecule-focused bioanalytical and biomarker contract research organization that, since its formation in 2003, has actively supported the evolving needs of companies developing biotherapeutics and biosimilars.
At our state-of-the-art testing facilities in Oxford, UK and St. Charles, USA we develop, transfer and validate large molecule PK, ADA and biomarker assays to our client’s specifications as well as offer a comprehensive listing of pre-qualified assays spanning decades of experience. With industry-leading capacity, we support studies ranging from a single plate to large multinational Phase III clinical trials. We have the capacity to handle variable sample numbers and large volumes to meet the needs of our clients.